Yuanyin Bio completed more than 280 million yuan in Series A financing

On June 21, Yuanyin Bio, which focuses on the development of new vaccines and multiple new therapeutic areas with international cutting-edge circular RNA technology, announced the successful completion of Series A financing of more than 280 million yuan… This financing was funded by a well-known industry investment institution and Hehe Jade Capital co-led the investment, followed by Sherpa Investment and Sanzheng Health Investment, and the old shareholders Quanchuang Capital and Qianji Capital also continued to make additional investment… After this round of financing, the construction of technology platforms, pipeline product research and development, and clinical trials will be accelerated. And registration declaration and international cooperation.
media coverage

Investment Community Venture Bangtou China Network

This article is reprinted from: https://readhub.cn/topic/8h1hprfeiA1
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment

Your email address will not be published.